Publikasi Scopus Covid-19 Per 14 Agustus 2024 (559 artikel)

Riset dan Pengabdian Masyarakat Do Research Sosial Service and Innovation

Publikasi Scopus Covid-19 Per 14 Agustus 2024 (559 artikel)

325

Authors

Hidayat R.; Mustika A.P.; Avisha F.; Djuliannisaa Z.; Winari D.D.; Putri R.A.; Lisman H.M.; Davin V.; Fathi G.C.; Widhani A.; Aini M.H.; Yudhistira; Azizah S.; Rahmadani M.; Istanti N.D.; Giantini A.

Full Names

Hidayat, Rakhmad (57225289998); Mustika, Alyssa Putri (57734141600); Avisha, Fhathia (57734240000); Djuliannisaa, Zlatikha (57209070722); Winari, Dinisa Diah (57734051700); Putri, Ria Amiliah (57734523000); Lisman, Heydi Marizky (57734051800); Davin, Vandra (57734051900); Fathi, Gemia Clarisa (57874096500); Widhani, Alvina (57202561455); Aini, Muhammad Hafiz (57734523100); Yudhistira (57666445700); Azizah, Siti (57441632500); Rahmadani, Meilisa (57222152743); Istanti, Novita Dwi (57734240100); G

Author S Id

57225289998; 57734141600; 57734240000; 57209070722; 57734051700; 57734523000; 57734051800; 57734051900; 57874096500; 57202561455; 57734523100; 57666445700; 57441632500; 57222152743; 57734240100; 12776781400

Title

Evaluation of SARS-CoV-2 Antibody Response Post Third Dose COVID-19 mRNA Vaccination at Universitas Indonesia Hospital

Year

2022

Source Title

Acta Medica Academica

Volume

Issue

Art No

Page Start

Page End

Page Count

Cited By

Link

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85141889020&doi=10.5644%2fama2006-124.374&partnerID=40&md5=0667ff2289dac1c7972937ec269bfb4a

Affiliations

Faculty of Medicine, Universitas Indonesia, Indonesia; Dr. Cipto Mangunkusumo Hospital, Indonesia; Universitas Indonesia Hospital, Indonesia

Authors With Affiliations

Hidayat R., Faculty of Medicine, Universitas Indonesia, Indonesia, Dr. Cipto Mangunkusumo Hospital, Indonesia, Universitas Indonesia Hospital, Indonesia; Mustika A.P., Faculty of Medicine, Universitas Indonesia, Indonesia, Dr. Cipto Mangunkusumo Hospital, Indonesia, Universitas Indonesia Hospital, Indonesia; Avisha F., Universitas Indonesia Hospital, Indonesia; Djuliannisaa Z., Faculty of Medicine, Universitas Indonesia, Indonesia, Dr. Cipto Mangunkusumo Hospital, Indonesia; Winari D.D., Universitas Indonesia Hospital, Indonesia; Putri R.A., Universitas Indonesia Hospital, Indonesia; Lisman H.M., Universitas Indonesia Hospital, Indonesia; Davin V., Universitas Indonesia Hospital, Indonesia; Fathi G.C., Universitas Indonesia Hospital, Indonesia; Widhani A., Faculty of Medicine, Universitas Indonesia, Indonesia, Dr. Cipto Mangunkusumo Hospital, Indonesia, Universitas Indonesia Hospital, Indonesia; Aini M.H., Faculty of Medicine, Universitas Indonesia, Indonesia, Dr. Cipto Mangunkusumo Hospital, Indonesia, Universitas Indonesia Hospital, Indonesia; Yudhistira, Universitas Indonesia Hospital, Indonesia; Azizah S., Faculty of Medicine, Universitas Indonesia, Indonesia, Universitas Indonesia Hospital, Indonesia; Rahmadani M., Universitas Indonesia Hospital, Indonesia; Istanti N.D., Universitas Indonesia Hospital, Indonesia; Giantini A., Faculty of Medicine, Universitas Indonesia, Indonesia, Dr. Cipto Mangunkusumo Hospital, Indonesia, Universitas Indonesia Hospital, Indonesia

Abstract

Objective. The longevity of vaccine effectiveness and antibody titer after the Moderna mRNA COVID-19 vaccination booster in healthcare workers in Indonesia is not known. Materials and Methods. We performed a prospective observational study of healthcare workers at the Universitas Indonesia Hospital after Moderna mRNA COVID-19 booster vaccination. An Immunol-ogy Analyzer with Chemiluminescence Immunoassay (CLIA) test was used to examine Anti SARS-CoV-2 S-RBD levels. Antibody levels were classified into two systems (3 categories, and 2 categories). Results. There were 31 male subjects (75.6%), 33 subjects (80.5%) aged 25-39 years, 17 subjects (41.5%) with overweight BMI, 35 subjects (85.4%) without comorbidities, and 29 subjects without previous history of COVID-19 infection (70.7%) who had antibody titer >1000 AU/ml. There were 27 subjects (65.9%) who had a booster shot ≥6 months after the second vaccination with antibody titer >1000 AU/ml. In this study, there was no significant correlation between antibody titer with factors such as gender, age, BMI, comorbidities, history of COVID-19 infection and time between the 2nd vaccination and booster vaccination. Conclusion. There is no significant correlation between antibody titer with factors such as gender, age, BMI, comorbidities, history of COVID-19 infection and time between the 2nd vaccination and booster vaccination. © 2022 by the Academy of Sciences and Arts of Bosnia and Herzegovina.

Author Keywords

COVID-19; SARS-CoV-2; Vaccine

Index Keywords

Antibodies, Viral; Antibody Formation; COVID-19; COVID-19 Vaccines; Hospitals; Humans; Indonesia; Male; RNA, Messenger; SARS-CoV-2; Vaccination; messenger RNA; virus antibody; antibody production; hospital; human; Indonesia; male; vaccination

Funding Details

Funding Text

Publisher

Academy of Sciences and Arts of Bosnia and Herzegovina

Issn

18401848

Isbn

Pubmed Id

36317998

Document Type

Article

Sjr Best Quartile